瑞舒伐他汀对慢性心力衰竭患者心功能的影响

目的观察瑞舒伐他汀对慢性心力衰竭患者血浆N-末端脑钠肽前体（NT—proBNP）、C-反应蛋白（CRP）水平及心功能的影响。方法将86例慢性心力衰竭患者随机分为治疗组和对照组，均予常规抗心衰治疗，治疗组加服瑞舒伐他汀钙．10mg／次，每天1次，疗程8周。治疗前后测定左心室射血分数（LVEF）、左心室舒张末期内径（LVEDD），血浆NT-proB—NP、CRP水平。结果治疗后治疗组和对照组总有效率分别为90．70％、69．77％，治疗组明显优于对照组（P〈0．05）；治疗后两组心功能指标LVEF明显升高，LVEDD明显下降，血浆NT—proBNP、CRP水平均明显下降（P〈0．05）。结论瑞舒伐他汀能降低血浆NT—proBNP、CRP水平，治疗慢性心力衰竭效果确切，无明显不良反应。

Effects of Rosuvastatin on heart function in patients with chronic heart failure

Objective To observe the effect of Rosuvastatin for the level of precursor plasma N-terminal brain natriuretic pep-tide （NT-proBNP）, C-reactive protein （CRP） level and heart function in patients with chronic heart failure. Methods 86 pa-tients with chronic heart failure were randomly divided into treatment group and control group, both groups were given con-ventional anti heart failure treatment, the treatment group added with Rosuvastatin Calcium, 10 mg/d, for 8 weeks. Before and after treatment, left ventrieular ejection fraction （LVEF）, left ventricular end-diastolic diameter （LVEDD）, plasma NT-proBNP and CRP levels were determined. Results After treatment, the total effective rate of treatment group and control group was 90.70%, 69.77% respectively, which of treatment group was better than that of control group （P 〈 0.05）. After treatment, in both groups, the cardiac function index of LVEF was markedly increased and LVEDD was significantly decreased, plasma NT-proBNP and CRP levels were both significantly decreased （P 〈 0.05）. Conclusion Rosuvastatin can reduce the level of plasma NT-proBNP and CRP, the treatment effect of which for chronic heart failure is exact, and it has no obvious adverse re-actions.